Literature DB >> 7993708

Epidemiology, pathogenesis, animal models, and treatment of Sjögren's syndrome.

R I Fox1.   

Abstract

Sjögren's syndrome is characterized by dry eyes (xerophthalmia) and dry mouth (xerostomia). Although general agreement exists about the ocular features of Sjögren's syndrome, significant controversy surrounds the classification criteria for defining the oral component. This has resulted in confusion in both the clinical and the research literature. The recent litigation involving silicone breast implants has forced clinicians to evaluate critically whether the condition of a particular patient fulfills specific diagnostic criteria for Sjögren's syndrome. Research studies have focused on potential genetic and environmental factors in the pathogenesis of Sjögren's syndrome. Studies of various ethnic populations have demonstrated an association with particular HLA-DR and -DQ alleles. However, the associated alleles are different for each ethnic group. No single environmental agent has been identified as a critical cofactor. Studies have concentrated on herpesviruses (Epstein-Barr virus and human herpesvirus type 6), hepatitis C virus, and retroviruses. Epstein-Barr virus isolated from patients has altered the ability to transform and lytically infect particular types of lymphocytes. Hepatitis C can lead to sicca symptoms, even in patients with relatively normal salivary gland biopsy findings. One report of Japanese patients indicated the presence of human T cell lymphotropic virus type I-like tax genes in the salivary biopsy specimens of a subset of patients and no gag, pol, or env sequences; this finding suggested a potential infection by a defective retrovirus. Studies on the pathogenesis have indicated that cytokines produced in the salivary gland are similar to T helper type 1 lymphocytes (interferon gamma).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7993708     DOI: 10.1097/00002281-199409000-00008

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  Effects of reduced saliva production on swallowing in patients with Sjogren's syndrome.

Authors:  Nicole M Rogus-Pulia; Jeri A Logemann
Journal:  Dysphagia       Date:  2010-10-28       Impact factor: 3.438

Review 2.  Multiple sclerosis in the elderly patient.

Authors:  Amer Awad; Olaf Stüve
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

3.  Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis.

Authors:  M Fujimoto; M Shimozuma; N Yazawa; M Kubo; H Ihn; S Sato; T Tamaki; K Kikuchi; K Tamaki
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

Review 4.  Geoepidemiology of autoimmune rheumatic diseases.

Authors:  Yinon Shapira; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Nat Rev Rheumatol       Date:  2010-06-22       Impact factor: 20.543

5.  Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes.

Authors:  K Koike; K Moriya; K Ishibashi; H Yotsuyanagi; Y Shintani; H Fujie; K Kurokawa; Y Matsuura; T Miyamura
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

6.  Sjögren's syndrome: History, clinical and pathological features.

Authors:  A L Parke; W W Buchanan
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

7.  TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren's syndrome.

Authors:  Seung-Ki Kwok; Mi-La Cho; Yang-Mi Her; Hye-Joa Oh; Mi-Kyung Park; Seon-Yeong Lee; Yun Ju Woo; Ji Hyeon Ju; Kyung-Su Park; Ho-Youn Kim; Sung-Hwan Park
Journal:  Arthritis Res Ther       Date:  2012-03-14       Impact factor: 5.156

8.  miR-744-5p contributes to ocular inflammation in patients with primary Sjogrens Syndrome.

Authors:  Joan Ní Gabhann-Dromgoole; Conor C Murphy; Qistina Pilson; Siobhan Smith; Caroline A Jefferies
Journal:  Sci Rep       Date:  2020-05-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.